STOCK TITAN

Sutro Biopharma - STRO STOCK NEWS

Welcome to our dedicated page for Sutro Biopharma news (Ticker: STRO), a resource for investors and traders seeking the latest updates and insights on Sutro Biopharma stock.

About Sutro Biopharma

Sutro Biopharma, Inc. (NASDAQ: STRO) is a clinical-stage biotechnology company that is revolutionizing the discovery, development, and manufacturing of next-generation cancer therapeutics. Leveraging its proprietary XpressCF® cell-free protein synthesis platform, Sutro designs and produces antibody-drug conjugates (ADCs) and bispecific antibodies with a precision and speed that surpass traditional cell-based methods. This innovative approach enables the company to rapidly iterate and optimize molecules for enhanced safety and efficacy, addressing critical unmet medical needs in oncology.

Core Technology and Competitive Advantage

Sutro’s XpressCF® platform eliminates the constraints of cell-based protein synthesis, allowing for the rapid and precise incorporation of non-natural amino acids into proteins. This technology underpins the development of homogeneous ADCs with site-specific conjugation, ensuring optimal therapeutic payload delivery to target tumors while minimizing off-target effects. The company also operates the world’s only cGMP cell-free manufacturing facility, located in San Carlos, California, providing a significant competitive edge in scalability and production efficiency.

Therapeutic Focus

The company’s clinical pipeline is centered on oncology, with a particular focus on cancers expressing folate receptor alpha (FRα). Its lead candidate, luveltamab tazevibulin (luvelta), is a registrational-stage ADC targeting FRα, currently being evaluated in multiple clinical trials for platinum-resistant ovarian cancer (PROC), endometrial cancer, and non-small cell lung cancer (NSCLC). Sutro is also advancing REFRαME-P1, a pivotal trial for pediatric acute myeloid leukemia (AML), a rare and aggressive cancer subtype. The company’s pipeline includes additional ADCs and immunostimulatory ADCs (iADCs) under development.

Revenue Streams and Collaborations

Sutro generates revenue through a combination of proprietary pipeline development and strategic collaborations. High-value partnerships with industry leaders like Ipsen, Astellas, and Merck validate its platform and provide non-dilutive funding. These collaborations often involve licensing agreements, milestone payments, and royalties, diversifying Sutro’s revenue streams while accelerating its R&D efforts.

Market Position and Challenges

Operating in the competitive oncology biotech sector, Sutro differentiates itself through its cell-free manufacturing technology, which enables rapid innovation and scalability. Key competitors include Seagen, ImmunoGen, and BioNTech, but Sutro’s focus on underserved patient populations and its robust pipeline position it as a significant player in ADC development. Challenges include high R&D expenses, regulatory hurdles, and the inherent risks of clinical trials.

Conclusion

Sutro Biopharma stands at the forefront of oncology innovation, leveraging its unique cell-free technology to develop targeted therapies that address critical gaps in cancer treatment. With a strong clinical pipeline, strategic partnerships, and a commitment to precision medicine, Sutro is poised to make a transformative impact in the field of oncology.

Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO) announced interim results from its Phase 1 study of STRO-002, a folate receptor alpha-targeting ADC for advanced ovarian cancer. The study, involving 44 patients with extensive prior treatments, reported an overall response rate (ORR) of 33%. Notably, patients starting at a 5.2 mg/kg dose level exhibited a 47% ORR. Encouraging safety signals included no new complications. Sutro plans to advance STRO-002 into further clinical phases, leveraging its Fast Track designation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.87%
Tags
-
Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO) has entered an exclusive license agreement with Tasly Biopharmaceuticals for the development and commercialization of STRO-002 in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan. Sutro will receive an upfront payment of $40 million and could earn up to $345 million in milestone payments. STRO-002 is currently in clinical trials for ovarian and endometrial cancers. Sutro retains rights outside of Greater China and will receive royalties based on STRO-002's net sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
none
-
Rhea-AI Summary

Sutro Biopharma (STRO) announced a KOL virtual event on Jan. 5, 2022, to share interim data from the Phase 1 study of STRO-002, an antibody-drug conjugate for advanced ovarian cancer. The trial, which enrolled 44 patients by Nov. 2021, aims to assess the efficacy, safety, and tolerability of STRO-002 in patients who have undergone multiple prior therapies. The event will feature presentations from Sutro management and Dr. R. Wendel Naumann from the Levine Cancer Institute.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
none
Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO) announced new nonclinical data for STRO-002 and STRO-001 presented at the ASH 2021 conference, showcasing potential therapies for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Research led by Fred Hutchinson Cancer Research Center identifies FOLR1 and CD74 as actionable targets. STRO-002 exhibited strong efficacy against high-risk AML subtypes, while STRO-001 demonstrated significant cytotoxicity in both AML and ALL cells. The data supports ongoing clinical trials for both products in treating various cancer indications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.91%
Tags
partnership conferences
-
Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO) announced CEO Bill Newell's participation in two virtual investor conferences. The Piper Sandler 33rd Annual Healthcare Conference is scheduled for November 22, 2021, at 10:00 a.m. ET, featuring a pre-recorded fireside chat. The 4th Annual Evercore ISI HealthCONx Conference will take place on November 30, 2021, at 10:05 a.m. ET, with a live fireside chat. Webcasts are accessible via Sutro's Investor Relations page, with archived replays available for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
conferences
-
Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO) announced the appointment of Heidi Hunter to its Board of Directors, effective November 17, 2021. Hunter brings over 25 years of biotech leadership experience, having held significant roles at Cardinal Health, UCB, Boehringer Ingelheim, and IQVIA. CEO Bill Newell highlighted her expertise in driving the development and commercialization of new medicines. Sutro focuses on advancing innovative cancer and autoimmune therapeutics, including its leading candidates STRO-001 and STRO-002, currently in Phase 1 trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
management
Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO) reported financial results for Q3 2021, highlighting a revenue drop to $8.5 million from $17.8 million in Q3 2020. Operating expenses surged to $43.2 million, reflecting increased R&D and G&A costs. Key developments include completed enrollment for the STRO-002 Phase 1 dose-expansion cohort targeting advanced ovarian cancer and ongoing dose escalation for STRO-001 in B-cell malignancies. Sutro has a cash runway into H2 2023, with substantial cash reserves of $254.2 million as of September 30, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
-
Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO), a clinical-stage drug development company, announced CEO Bill Newell will present at three virtual investor conferences in November 2021. The presentations include:

  • Credit Suisse 30th Annual Healthcare Conference: Nov. 10, 2021, 4:20 p.m. EST
  • Stifel Virtual Healthcare Conference: Nov. 15, 2021, 1:20 p.m. EST
  • Jefferies London Healthcare Conference: Nov. 18, 2021, 3:00 a.m. EST

Live webcasts can be accessed via the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
conferences
-
Rhea-AI Summary

Sutro Biopharma and BioNova Pharmaceuticals have announced an option agreement for the development and commercialization of STRO-001, a CD74-targeting ADC, in Greater China. BioNova will pay Sutro an initial $4 million and potential milestone payments totaling up to $200 million. Sutro maintains global rights outside Greater China. The collaboration aims to address unmet medical needs in hematologic cancers, with BioNova committed to advancing STRO-001 through clinical development and regulatory approval. Sutro will receive tiered royalties based on sales in the region.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
none
Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO) announced on Sept 30, 2021, an extension of its research term for the cytokine derivative program with Merck for an additional two years, aimed at completing preclinical research for a second candidate. Sutro is eligible for up to $10 million from this extension. The collaboration leverages Sutro's proprietary protein engineering platforms, XpressCF® and XpressCF+™, and has previously resulted in milestone payments of $5 million and $15 million for earlier collaborations. The ongoing research could lead to innovative cancer treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
none

FAQ

What is the current stock price of Sutro Biopharma (STRO)?

The current stock price of Sutro Biopharma (STRO) is $1.47 as of March 6, 2025.

What is the market cap of Sutro Biopharma (STRO)?

The market cap of Sutro Biopharma (STRO) is approximately 112.1M.

What is Sutro Biopharma's core technology?

Sutro Biopharma utilizes its proprietary XpressCF® cell-free protein synthesis platform to develop antibody-drug conjugates (ADCs) and bispecific antibodies with enhanced precision and speed.

What are Sutro Biopharma's lead clinical programs?

Sutro's lead candidate is luveltamab tazevibulin (luvelta), an ADC targeting folate receptor alpha (FRα), currently in trials for ovarian cancer, endometrial cancer, and non-small cell lung cancer.

How does Sutro Biopharma generate revenue?

Sutro generates revenue through proprietary pipeline development and collaborations with pharmaceutical companies, involving licensing agreements, milestone payments, and royalties.

What makes Sutro Biopharma unique in the oncology biotech space?

Sutro’s cell-free XpressCF® platform enables rapid and precise protein synthesis, allowing for the development of homogeneous ADCs with site-specific conjugation, offering a competitive advantage in scalability and innovation.

Who are Sutro Biopharma's key competitors?

Sutro competes with companies like Seagen, ImmunoGen, and BioNTech in the oncology ADC space but differentiates itself with its proprietary cell-free manufacturing technology.

What is the significance of Sutro's cell-free manufacturing facility?

Sutro operates the world’s only cGMP cell-free manufacturing facility, enabling scalable and efficient production of its therapeutic candidates.

What types of cancers does Sutro Biopharma target?

Sutro focuses on cancers expressing folate receptor alpha (FRα), including ovarian cancer, endometrial cancer, non-small cell lung cancer, and pediatric acute myeloid leukemia (AML).

What partnerships does Sutro Biopharma have?

Sutro collaborates with industry leaders like Ipsen, Astellas, and Merck, which provide funding and validate its platform through licensing and milestone agreements.

What are the risks associated with Sutro Biopharma's business model?

Risks include high R&D costs, regulatory hurdles, dependence on clinical trial success, and competition from established biotech companies.

What is the significance of Sutro's ADC pipeline?

Sutro’s ADC pipeline aims to address unmet medical needs in oncology, offering targeted therapies with improved safety and efficacy profiles for underserved patient populations.
Sutro Biopharma

Nasdaq:STRO

STRO Rankings

STRO Stock Data

112.14M
79.05M
0.94%
77.19%
4.67%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO